Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$1.90 USD
-0.04 (-2.06%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $1.89 -0.01 (-0.53%) 5:56 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Aerovate Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 81 | 53 | 23 | 9 | 3 |
Income After Depreciation & Amortization | -81 | -53 | -23 | -9 | -3 |
Non-Operating Income | 6 | 2 | 0 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -75 | -51 | -23 | -10 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -76 | -52 | -23 | -10 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -76 | -52 | -23 | -10 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -84 | -54 | -23 | -9 | -3 |
Depreciation & Amortization (Cash Flow) | -3 | -1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -81 | -53 | -23 | -9 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.33 | 24.47 | 12.29 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.87 | -2.10 | -1.87 | NA | NA |
Diluted Net EPS (GAAP) | -2.87 | -2.10 | -1.87 | -40.31 | NA |
Fiscal Year end for Aerovate Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 26.17 | 24.62 | 22.06 | 21.36 | 20.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -26.17 | -24.62 | -22.06 | -21.36 | -20.33 |
Non-Operating Income | 1.39 | 1.43 | 1.71 | 1.81 | 1.31 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -24.78 | -23.19 | -20.36 | -19.56 | -19.03 |
Income Taxes | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -24.78 | -23.19 | -20.41 | -19.56 | -19.03 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -24.78 | -23.19 | -20.41 | -19.56 | -19.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 28.76 | 27.80 | 27.70 | 27.64 | 25.17 |
Diluted EPS Before Non-Recurring Items | -0.86 | -0.83 | -0.74 | -0.71 | -0.76 |
Diluted Net EPS (GAAP) | -0.86 | -0.83 | -0.73 | -0.71 | -0.76 |